Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.
Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.